Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.

ABSTRACT:

Importance

Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression.

Objective

To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM.

Design, setting, and participants

The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 yea

SUBMITTER: Vissing CR 

PROVIDER: S-EPMC10483382 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature